Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer.
By: Hung-Lung Ke, Hung-Pin Tu, Hui-Hui Lin, Chee-Yin Chai, Lin-Li Chang, Wei-Ming Li, Ching-Chia Li, Yi-Chen Lee, Hsin-Chih Yeh, Wen-Jeng Wu, Da-Tian Bau

Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, 100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan, ROC.
2012-9-21; doi:
Abstract

Background

There are no reliable biomarkers for diagnosis, prediction of outcome or treatment effect monitoring for upper tract urothelial carcinoma (UTUC), which is a uniquely prevalent cancer in Taiwan. In the present study, 128 primary UTUC specimens of various grades and primary tumor status were examined for the expression of cyclooxygenase-2 (COX-2) in tumor and stroma tissues aiming to clarify the association of COX-2 expression with clinical outcomes in Taiwanese patients with UTUC.

Materials

Immunohistochemistry was implemented to investigate COX-2 expression levels in 128 paired tumor and stroma specimens. The association of COX-2 expression with tumor progression and prognosis was analyzed.

Results

Our data demonstrated that positive COX-2 expression was more frequent in stromal cells (57.0%), than in tumor sites (53.1%), and the up-regulation of COX-2 was strongly associated with higher cancer-specific death and cancer recurrence rates. In COX-2-negative cases, no similar correlation was found.

Conclusion

COX-2 expression was up-regulated in both stromal and tumor cells of more than half of the studied UTUC patients and the positive expression of COX-2 in stromal cells may be a potential predictive and prognostic biomarker for UTUC, especially for cancer-specific death and recurrence.





PMID:22993369






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements